MT-802

• CAT Number: I018737
• CAS Number: 2231744-29-7
• Molecular Formula: C₄₁H₄₁N₉O₈
• Molecular Weight: 787.82
• Purity: ≥95%
• Target: Protein Tyrosine Kinase/RTK
• IUPAC Name: 2-[2-[2-[4-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]ethoxy]ethoxy]-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]acetamide
• InChI: InChI=1S/C41H41N9O8/c42-37-35-36(25-6-9-29(10-7-25)58-28-4-2-1-3-5-28)47-50(38(35)44-24-43-37)27-14-16-48(17-15-27)18-19-56-20-21-57-23-34(52)45-26-8-11-30-31(22-26)41(55)49(40(30)54)32-12-13-33(51)46-39(32)53/h1-11,22,24,27,32H,12-21,23H2,(H,45,52)(H2,42,43,44)(H,46,51,53)
• InChIKey: AJTLGUJXIKEZCQ-UHFFFAOYSA-N
• SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)COCCOCCN4CCC(CC4)N5C6=NC=NC(=C6C(=N5)C7=CC=C(C=C7)OC8=CC=CC=C8)N

MT-802(CAT: I018737) is a highly potent Bruton’s Tyrosine Kinase (BTK) degrader developed using PROTAC (Proteolysis Targeting Chimera) technology. It selectively induces the ubiquitination and degradation of BTK, including the C481S mutant form, which is resistant to traditional BTK inhibitors. MT-802 exhibits a DC₅₀ of 1 nM for BTK degradation, with a DC₅₀ of 9.1 nM and maximal degradation observed at 250 nM. This targeted degradation approach offers a promising therapeutic strategy for treating chronic lymphocytic leukemia (CLL) and other B-cell malignancies, especially in patients harboring drug-resistant BTK mutations.